SWX:SFZN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Siegfried Holding AG engages in the life sciences business worldwide. More Details

Rewards

Earnings are forecast to grow 28.98% per year

Risk Analysis

No risks detected for SFZN from our risk checks.


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Siegfried Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SFZN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: SFZN's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-6.5%

SFZN

1.2%

CH Life Sciences

0.4%

CH Market


1 Year Return

29.7%

SFZN

62.0%

CH Life Sciences

-0.4%

CH Market

Return vs Industry: SFZN underperformed the Swiss Life Sciences industry which returned 62% over the past year.

Return vs Market: SFZN exceeded the Swiss Market which returned -0.4% over the past year.


Shareholder returns

SFZNIndustryMarket
7 Day-6.5%1.2%0.4%
30 Day-1.9%6.9%2.8%
90 Day-2.8%0.8%5.8%
1 Year30.5%29.7%62.7%62.0%3.1%-0.4%
3 Year92.3%88.4%129.6%124.3%19.8%4.7%
5 Year249.2%236.4%289.8%264.3%51.9%26.8%

Long-Term Price Volatility Vs. Market

How volatile is Siegfried Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Siegfried Holding undervalued compared to its fair value and its price relative to the market?

59.57x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: SFZN (CHF618) is trading above our estimate of fair value (CHF526.76)

Significantly Below Fair Value: SFZN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SFZN's PE Ratio (59.6x) is in line with the XE Life Sciences industry average.

PE vs Market: SFZN is poor value based on its PE Ratio (59.6x) compared to the Swiss market (24.5x).


Price to Earnings Growth Ratio

PEG Ratio: SFZN is poor value based on its PEG Ratio (2.1x)


Price to Book Ratio

PB vs Industry: SFZN is good value based on its PB Ratio (3.7x) compared to the XE Life Sciences industry average (5.3x).


Next Steps

Future Growth

How is Siegfried Holding forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

29.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SFZN's forecast earnings growth (29% per year) is above the savings rate (-0.3%).

Earnings vs Market: SFZN's earnings (29% per year) are forecast to grow faster than the Swiss market (13% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SFZN's revenue (8.5% per year) is forecast to grow faster than the Swiss market (4.6% per year).

High Growth Revenue: SFZN's revenue (8.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SFZN's Return on Equity is forecast to be low in 3 years time (13%).


Next Steps

Past Performance

How has Siegfried Holding performed over the past 5 years?

10.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SFZN has high quality earnings.

Growing Profit Margin: SFZN's current net profit margins (5.2%) are lower than last year (7.1%).


Past Earnings Growth Analysis

Earnings Trend: SFZN's earnings have grown by 10.2% per year over the past 5 years.

Accelerating Growth: SFZN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SFZN had negative earnings growth (-26%) over the past year, making it difficult to compare to the Life Sciences industry average (31.5%).


Return on Equity

High ROE: SFZN's Return on Equity (6.2%) is considered low.


Next Steps

Financial Health

How is Siegfried Holding's financial position?


Financial Position Analysis

Short Term Liabilities: SFZN's short term assets (CHF599.2M) exceed its short term liabilities (CHF168.5M).

Long Term Liabilities: SFZN's short term assets (CHF599.2M) exceed its long term liabilities (CHF307.4M).


Debt to Equity History and Analysis

Debt Level: SFZN is debt free.

Reducing Debt: SFZN has no debt compared to 5 years ago when its debt to equity ratio was 46.1%.

Debt Coverage: SFZN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: SFZN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Siegfried Holding current dividend yield, its reliability and sustainability?

0.45%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: SFZN's dividend (0.45%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.62%).

High Dividend: SFZN's dividend (0.45%) is low compared to the top 25% of dividend payers in the Swiss market (3.79%).


Stability and Growth of Payments

Stable Dividend: SFZN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.

Growing Dividend: SFZN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: SFZN is not paying a notable dividend for the Swiss market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SFZN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Wolfgang Wienand (48 yo)

2yrs

Tenure

Dr. Wolfgang Wienand has been Chief Executive Officer at Siegfried Holding AG since January 01, 2019. Dr. Wienand has been President and Chief Executive Officer since January 2019 at Siegfried AG. Dr. Wien...


Leadership Team

NamePositionTenureCompensationOwnership
Wolfgang Wienand
Chief Executive Officer2yrsno data0.40%
CHF 10.3m
Reto Suter
Chief Financial Officer3.67yrsno data0.096%
CHF 2.5m
René Imwinkelried
Global Head of Technical Operations4.17yrsno data0.24%
CHF 6.1m
Jürgen Roos
Chief Scientific Officer1.75yrsno data0.0034%
CHF 86.5k
Peter Kiechle
Chief Compliance Officer18yrsno datano data
Luca Torre
General Counsel & Secretary2yrsno datano data
Peter Gehler
Chief Communications Officer21yrsno datano data
Marianne Späne
Global Head of Business Development10.83yrsno data0.62%
CHF 15.8m
Arnoud Middel
Global Head of Human Resources9.33yrsno data0.11%
CHF 2.8m
Enno Schweinberger
Head of Quality Assurance & Qualified Person Siegfried Ltdno datano datano data
Daniel Nieper
Chief Strategy Officer2yrsno datano data

3.9yrs

Average Tenure

55yo

Average Age

Experienced Management: SFZN's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Colin Bond
Independent Non-Executive Director8yrsCHF205.15k0.076%
CHF 1.9m
Andreas Casutt
Independent Chairman7yrsCHF430.56k0.46%
CHF 11.7m
Isabelle Welton
Additional Director0.75yrno datano data
Wolfram Carius
Independent Non-Executive Director7yrsCHF195.51k0.064%
CHF 1.6m
Reto Garzetti
Independent Non-Executive Director9.67yrsCHF215.73k0.20%
CHF 5.1m
Ulla Schmidt
Independent Non-Executive Director5yrsCHF195.51k0.040%
CHF 1.0m
Martin Schmid
Independent Director5yrsCHF226.30k0.040%
CHF 1.0m

7.0yrs

Average Tenure

59yo

Average Age

Experienced Board: SFZN's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Siegfried Holding AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Siegfried Holding AG
  • Ticker: SFZN
  • Exchange: SWX
  • Founded: 1873
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF2.566b
  • Shares outstanding: 4.15m
  • Website: https://www.siegfried.ch

Number of Employees


Location

  • Siegfried Holding AG
  • Untere BrUehlstrasse 4
  • Zofingen
  • Aargau
  • 4800
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SFZNSWX (SIX Swiss Exchange)YesRegistered SharesCHCHFJun 1994
0QQOLSE (London Stock Exchange)YesRegistered SharesGBCHFJun 1994
SQGDB (Deutsche Boerse AG)YesRegistered SharesDEEURJun 1994
SGFE.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDJun 1994

Biography

Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, includi...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 18:16
End of Day Share Price2021/01/15 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.